HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Patients With HER2+ Breast Cancer Who Achieve pCR With Neoadjuvant HER2-Targeted Therapy Have Better DFS, OS

February 9th 2022

Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.

FLAMINGO-01 Trial Examining Adjuvant GLSI-100 in HER2+ Breast Cancer Approaches Initiation

February 2nd 2022

Significant progress has been made toward the initiation of the phase 3 FLAMINGO-01 trial, which will evaluate the combination of the immunotherapy GP2 with granulocyte macrophage colony stimulating factor in the adjuvant treatment of HER2/neu- and HLA-A*02–positive patients following surgery and trastuzumab-based therapy.

Breast Cancer Paradigm Pushes Forward With Novel Agents, Sequencing Strategies, and Dynamic Biomarkers

January 29th 2022

Aditya Bardia, MD, MPH, discusses key updates in HER2-positive, hormone receptor–positive, and triple-negative breast cancers, as well as the evolving clinical application of gene signature assays, liquid biopsies, and genotyping.

NCCN Guidelines Include Neratinib-Based Recommendations for HER2+ Breast Cancer

January 24th 2022

The National Comprehensive Cancer Network guidelines were updated for 2022 regarding the treatment of patients with breast cancer to include 2 new recommendations involving neratinib.

Dr. Cole on Next Steps With Tucatinib in HER2+ Breast Cancer

January 19th 2022

John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.

NHS Scotland Accepts Trastuzumab Deruxtecan for Use in HER2+ Metastatic Breast Cancer

January 17th 2022

The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have previously received 2 or more anti–HER2-based therapies.

FDA Grants Priority Review to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Cancer

January 17th 2022

The FDA has granted priority review to the supplemental biologics license application of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen.1

Dr. Mortimer on the Potential Benefit of Tucatinib Plus ADCs in HER2+ Breast Cancer

January 14th 2022

Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.

Dr. Hurvitz on the Clinical Implications of the SUMMIT Trial in HER2-Mutated Breast Cancer

January 14th 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the ongoing phase 2 SUMMIT trial in HER2-mutated breast cancer.

Dr. Tolaney on the Efficacy of Zanidatamab Plus Chemo in HER2+ Breast Cancer

January 14th 2022

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer.

Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast Cancer

January 12th 2022

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

Dr. Krop Discusses Progress Made in Metastatic HER2+ Breast Cancer

January 12th 2022

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast Cancer

January 12th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Maintains PFS Benefit Across Subgroups in HER2+ Metastatic Breast Cancer

January 12th 2022

Sara Hurvitz, MD, discusses the findings from the subgroup analysis of the DESTINY-Breast03 trial, and future research directions for trastuzumab deruxtecan.

Dr. Rimawi on the Promise of the HER2CLIMB-02 Trial in HER2+ Breast Cancer

January 11th 2022

Mothaffar Fahed Rimawi, MD, discusses the promise of the phase 3 HER2CLIMB-02 trial in HER2-positive metastatic breast cancer.

Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

January 6th 2022

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Tucatinib Triplet Maintains OS Benefit in HER2+ Breast Cancer With Brain Metastases

January 6th 2022

The combination of tucatinib, trastuzumab, and capecitabine continued to produce an improvement in overall survival compared with trastuzumab/capecitabine alone in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases.

GlobalData Projects Continued Growth of HER2+ Breast Cancer Market

January 5th 2022

Driven by the anticipated launches of 5 pipeline agents and the label expansions of currently marketed drugs, theHER2-postive breast cancer market is expected to experience low growth from 2020 to 2030.

EMA Validates Type II Variation Application for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

January 3rd 2022

The European Medicines Agency has validated the Type II Variation application for fam-trastuzumab deruxtecan-nxki as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 1 or more anti–HER2-based regimens.

Dr. Rimawi on the Clinical Implications of the FeDeriCa Trial in Early-Stage HER2+ Breast Cancer

December 22nd 2021

Mothaffar Fahed Rimawi, MD, discusses the clinical implications of the phase 3 FeDeriCa trial in early-stage, HER2-positive breast cancer.